The abstract is read at the publisher; the summary is JClub's.
Adjuvant nivolumab after upfront surgery did not improve disease-free survival versus observation in resected non-small cell lung cancer, with median 71.3 vs 68.8 months.
- Why it matters: It addresses whether nivolumab given after planned adjuvant chemotherapy and/or radiotherapy adds benefit beyond preoperative/perioperative use in resected disease.
- What they did: In an open-label phase 3 trial (378 US centers), 466 patients received nivolumab 480 mg IV every 4 weeks for up to 1 year and 469 received observation; co-primary endpoints were disease-free survival in all-comers and those with PD-L1 ≥50%.
- The result: Disease-free survival was similar in the intention-to-treat group (HR 0.97; 1-sided P=.39) and in PD-L1 ≥50% (HR 0.86; 1-sided P=.22), so the trial was stopped for futility.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access